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Abstract 
 Familial hypercholesterolemia (FH) is a common genetic condition that can have serious 
implications in adulthood such as premature coronary disease, stroke, and peripheral vascular 
disease if not adequately diagnosed in childhood. “Globally, one baby is born with FH every 
minute” (Wiegman et al., 2015, p. 2425).  Individuals with familial hypercholesterolemia can 
have a normal life expectancy if diagnosed and treated early in childhood. This independent 
study aims to improve awareness of the need for early detection of FH children through the 
implementation of universal screening.  
 Cascade screening, also known as selective screening, based on family history is 
currently being used in clinical practice to identify affected individuals, but many with FH are 
undiagnosed during childhood by relying on this strategy (Ferranti, 2015).  Recent American 
guidelines have been released recommending that selective screening “in the presence of a 
positive family history of elevated cholesterol or premature cardiovascular disease beginning at 
age 2 years AND universal screening at age 9-11 years, with repetition of the process at age 17-
20 years” (Sullivan, Freeman, Molloy, & Williams, 2015, p. 3).  Identifying FH early and 
subsequently lowering LDL-C over the lifespan reduces the collective LDL-C burden to 
potentially prevent the complications that are associated with FH. The purpose of this 
independent study is to provide an agenda for further progress in screening for familial 
hypercholesterolemia, building on the foundation provided by recent guidelines.  Increased 
awareness and early identification of FH is critical to improve the lifespan for children and 
adolescents with FH.  
 Keywords: familial hypercholesterolemia, cascade screening, universal screening 
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Universal screening for hypercholesterolemia in primary care  
Background 
 “Familial hypercholesterolemia (FH) is an autosomal dominant disorder of low-density 
lipoprotein (LDL) metabolism leading to high LDL cholesterol (LDL-C) and accelerated 
atherosclerosis” (Ferranti, 2015, p. S11).  There is a rare homozygous form of familial 
hypercholesterolemia that is correlated with coronary heart disease and abnormal assessment 
findings during childhood. The more common heterozygous form (hetFH) is “asymptomatic until 
adulthood” (Ferranti, 2015, p. S11). Familial hypercholesterolemia is diagnosed either on 
phenotypic criteria or positive genetic testing. Phenotypic criteria includes, “an elevated low-
density lipoprotein cholesterol (LDL-C) level plus a family history of elevated LDL-C, 
premature coronary artery disease and/or genetic diagnosis” (Wiegman et al., 2015, p. 2426).  
Screening is crucial in order to identify affected individuals due to the high prevalence rate. FH 
is one of the most common genetic disorders, affecting 1 in 200 to 500 people in the European 
population; thus making familial hypercholesterolemia more common than Down syndrome 
(Safeer, 2015).   
Cascade screening, also known as selective screening, is “a strategy in which the 
diagnosis is confirmed in an index case, after which it is sought in close family members in a 
cascade fashion” (Sullivan, Freeman, Molloy, & Williams, 2015, p. 4).  In familial 
hypercholesterolemia, a vertical pattern of inheritance produces a 50% chance of inheritance in 
first-degree relatives and a 25 % chance of inheritance in second-degree relatives. Universal 
screening refers to, “a case detection strategy in which the diagnosis in question has been sought 
in every individual in the population” (Sullivan et al., 2015, p. 2). Universal screening promotes 
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reverse cascade screening. By identifying children with total cholesterol levels > 200 mg/dL 
through universal screening, providers will consequently identify many parents at risk who may 
never have been previously evaluated for hypercholesterolemia (Benuck, 2015).  
Cascade screening is currently being performed in clinical practice based on a patient’s 
family history. Although this can identify affected individuals, many people with hetFH go 
undiagnosed when relying on cascade screening alone. “Overall, estimates are that fewer than 
25% of persons with FH are diagnosed” (Ned & Sijbrands, 2011, p. 1).  Individuals with 
untreated FH are 100-times more likely to develop cardiovascular disease and atherosclerosis as 
young adults when compared to individuals without FH (Boyles, 2015).  By screening the entire 
population at a specified interval, consistent diagnoses can be made to appropriately treat those 
affected individuals and prevent future complications. Early detection and treatment of familial 
hypercholesterolemia bids one of the “most effective interventions for further reduction in the 
incidence of premature coronary disease, stroke, and peripheral vascular disease” (Sullivan et al., 
2015, p. 1). The benefits of implementing universal lipid screening will not only appropriately 
identify children and families that are heFH, but will also detect those with abnormal lipid 
patterns, which has been noted to be roughly 20% of the pediatric population (Benuck, 2015).   
Case Report 
History of Presenting Illness 
 A 24-year-old male presents to the clinic requesting that his cholesterol be checked 
related to family history. The patient’s father recently died at the age of 46 while shoveling 
snow; therefore, the patient is requesting further screening. His brother has been on 
pharmacological medications for high cholesterol for roughly one year. There are no other first 
degree relatives that the patient is aware of with a medical history of hyperlipidemia.  
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Past Medical History/Surgical History 
 No significant past medical history is noted. He has a past medical history of allergic 
rhinitis and a surgical history to include tonsillectomy and adenoidectomy at four years of age.  
Patient’s medication regimen limited to a Zyrtec as needed.  He is up to date with all 
immunizations.  He is allergic to pollen. He has no known drug allergies.  
Family History 
 As noted in the history of presenting illness, the patient’s father recently passed away of 
cardiac complications at the age of 46 and had hyperlipidemia. The patient’s brother is currently 
being treated for hypercholesterolemia. There are no other first degree relatives that the patient is 
aware of with a medical history of hyperlipidemia. 
Social History 
The patient is a college student that refrains from tobacco use and recreational drugs.  He 
denies any exposure to secondhand smoke. He admits to drinking one to two alcoholic beverages 
several nights out of the week and drinks one to two caffeinated beverages per day.  He exercises 
for at least 30 minutes per day five days per week.  He denies any overwhelming life stressors 
and feels as if he copes with daily stress well.  
Review of Systems 
 The patient denies any constitutional symptoms such as fever, sleep disturbance, 
weakness, fatigue, or unexplained weight loss or gain.  He denies any changes in vision, upper 
respiratory symptoms, or headaches.  He denies symptoms of shortness of breath, chest pain, 
palpitations, edema, irregular heartbeat, or murmur.  He denies experiencing loss of balance, 
dizziness, or numbness to any of his extremities.  He denies any changes in bowel or bladder 
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such as dysuria, urinary frequency, hematuria, or hematochezia.  He denies any dermatologic 
concerns such as rashes, wounds, or lesions.  
Physical Examination 
 Patient is 6’1” and 200 lbs. with a Body Mass Index of 26.4.  Vitals signs are as follows: 
BP 110/54; HR 62; Temperature 37.1 degrees Celsius. Patient is alert, oriented, cooperative, and 
appears to be in no acute distress. He makes appropriate eye contact and is able to verbalize in a 
clear and understandable manner.  A steady gait is noted while in the examination room. The 
thyroid gland was palpated with no evidence of nodules or enlargement on examination. His 
pupils are equal, round, and reactive to light. His lung sounds are clear throughout all lung fields 
with no wheezing, cough, or shortness of breath noted on examination. His heart sounds are 
regular with S1 S2 noted upon auscultation. Heart sounds are free of murmur, ectopy, or 
irregularity. There are no carotid bruits present on auscultation. His bowel sounds are active in 
all four quadrants of the abdomen.  There is appropriate dullness and tympany noted with 
percussion of the various anatomical structures of the abdomen. There is no tenderness of the 
abdomen upon light and deep palpation of all four quadrants of the abdomen. There is no 
hepatosplenomegaly or CVA tenderness noted. His peripheral pulses are strong, regular, and 
intact. There is no evidence of peripheral edema noted. His skin is warm and dry with no areas of 
concern present on examination.  
Laboratory Findings 
 Based upon the patient’s family history of hyperlipidemia, a fasting lipid panel as well as 
a comprehensive metabolic panel was obtained with the results as follows: 
COMPREHENSIVE 
METABOLIC PANEL 
REFERENCE RANGE PATIENT RESULT 
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SERUM BUN 7-22 mg/dL 18 
SODIUM 136-145 mmol/L 139 
POTASSIUM 3.6-5.5 mmol/L 3.9 
CHLORIDE 98-109 mmol/L 102 
SERUM GLUCOSE 70-99 mg/dL 86 
SERUM CREATININE 06-1.3 mg/dl 1.1 
CALCIUM 8.8-10.5 mg/dL 9.8 
ANION GAP 5-13 mmol/L 9.7 
GFR CALCULATED ML/MIN/1.73 SQUARE M >60 
SERUM ALBUMIN 3.4-4.7 g/dL 4.00 
ALKALINE PHOSPHATASE 50-136 U/L 88 
TOTAL PROTEIN 5.97.6 g/dL 7.4 
TOTAL BILIRUBIN 0.2-1.2 mg/dl 0.4 
AST 5-34 U/L 20 
ALT 7-55 U/L 22 
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 Based on the patient’s fasting lipid profile and significant family history of 
hyperlipidemia, the patient was diagnosed with familial hyperlipidemia.  He was initiated on 
simvastatin 40 mg daily.  He was informed to re-check his liver function tests in one month for 
drug safety monitoring. He will have a follow-up visit in three months with a fasting lipid profile 
and a comprehensive metabolic panel completed prior to that three month appointment. A 
detailed discussion was conducted in regards to his current alcohol consumption while taking the 
simvastatin due to the risk of liver toxicity.  Education was provided on stress management and 
exercise as this may assist in improving his overall health. Education was also provided on 
promoting a diet low in saturated fats.  Educational handouts were provided and the patient is in 
agreement to visit with a nutritionist.  A referral was placed for the patient to schedule this at his 
convenience.  
Search Strategies 
The University of North Dakota’s Harley French Library website was utilized for 
gathering literature.  The focal point for this literature search was primarily centered on familial 
hypercholesterolemia and cascade screening. PubMed was the first avenue utilized for the 
literature search as this is noted to be “comprised of over 24 million citations for biomedical 
literature from MEDLINE,  life science journals, and online books” (National Center for 
Biotechnology Information [NCBI], n.d., para. 1 ).  This database specializes in “reviews of 
clinical effectiveness research, with easy-to-read summaries for consumers as well as full 
technical reports” (UND Harley French Library of the Health Sciences website, 2011, p. 1).  
PubMed is free for users and is successfully managed by the National Center for Biotechnology 
Information that is located at the National Institutes of Health (NCBI, n.d., para. 2). The first 
medical subject heading, MeSH, terminology utilized in this search focused on “familial 
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hypercholesterolemia” AND “cascade screening”. This yielded 117 results.  The English filter 
was added, resulting in 110 results. The search was then refined to include articles within the last 
5 years, resulting in 71 results.  The focus of this literature search is universal screening; 
however, there has not been many publications on this specific screening as new 
recommendations were implemented in 2015. By incorporating cascade screening in the MeSH 
terminology, research comparing cascade screening and universal screening was noted and 
applicable to the research topic. It was noted through many attempts that this was the best route 
to search the question at hand.   After selecting the articles and filtering many were eliminated 
due to either redundancy or to insignificant applicability to the present topic.  Therefore, a total 
of 15 articles via the PubMed database as well as one outside article were utilized in this 
literature review.  
Literature Review 
 Familial hypercholesterolemia (FH) is an autosomal-dominant genetic disease that is 
present in all racial and ethnic groups that is correlated with premature atherosclerotic coronary 
heart disease. The heterozygous FH has the highest prevalence of genetic defects; thus causing 
significant premature mortality (American Heart Association, Inc., 2015).  Extensive research has 
been completed on genetic testing, implications of acquiring familial hypercholesterolemia, and 
treatment modalities.  Despite these advances in research, “FH remains underdiagnosed and 
undertreated worldwide” (American Heart Association, Inc., 2015, p. 2167).  According to the 
American Heart Association (2015), a majority of patients receive treatment in primary care 
settings without knowing the implications of the genetic disease itself. Dr. Stephen Daniels, a 
pediatric cardiologist, noted in a recent article that children in the United States are often not being 
screened for familial hypercholesterolemia (Boyles, 2015).  Dr. Stephen Daniels stated, “We have 
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this epidemic of childhood obesity, so the focus seems to be on screening children who are 
overweight, but the truth is that most kids who have genetic dyslipidemias are not overweight” 
(Boyles, 2015, p. 2).  Guidelines have been published to improve the awareness of familial 
hypercholesterolemia. Improved identification of individuals with FH at a young age has become 
a priority due to the correlation between lifelong exposure to elevated LDL-C levels and ischemic 
heart disease (American Heart Association, 2015).   
Similar to the case report depicted in this independent study, many people seek medical 
advice for cholesterol monitoring once a first-degree relative has been diagnosed with 
hypercholesterolemia or deceased from a complication of hypercholesterolemia.  In the case of the 
24-year-old male with the positive family history his total cholesterol was noted to be 310 with an 
LDL of 209, placing him at significant risk of future cardiovascular events if left untreated. This 
patient willingly came in requesting to have his cholesterol levels checked after the passing of his 
father at the age of 46.  Based on the new guidelines recommending that universal screening be 
completed at age 9-11 years with repetition of the process at age 17-20 years, this particular 24-
year-old patient may have already been diagnosed and treated for familial hypercholesterolemia; 
thus, preventing the cumulative LDL burden that has perpetuated up until the age of 24. 
Furthermore, had the universal screening been implemented in this patient during childhood, his 
deceased father may have been diagnosed or perhaps more aggressively treated through the 
concept of reverse cascade screening.  A review of the literature acquired will be presented 
throughout this section illustrating the advantages and disadvantages between cascade and 
universal screening. There are fewer studies available in regards to universal screening in younger 
children merely due to the fact that recent guidelines advocating for universal screening were 
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released in 2015. The research does; however, provide evidence that favors universal screening 
due to the prevention of people going undiagnosed as seen in cascade screening.  
 Evidence supports the concept that familial hypercholesterolemia causes pathological 
changes to the cardiovascular system at an early age. Thus, the recommendations were released 
for “selective screening in the presence of a positive family history of elevated cholesterol or 
premature cardiovascular disease beginning at age 2 years AND universal screening at age 9-11 
years, with repetition of the process at age 17-20 years”  (Sullivan et al., 2015, p. 3).  Both the 
USPSTF and the American Academy of Family Physicians indicated that there is insufficient 
evidence to screen asymptomatic children and adolescents for FH; however, these new 
recommendations based on expert opinion and the National Heart, Lung, and Blood Institute 
(NHLBI) suggest universal screening. The American Academy of Pediatrics has also adopted these 
recommendations (Safeer, 2015). The time frame of 9-11 years recognizes that detection of FH by 
measurement of LDL or total cholesterol is optimum between these years.  Re-evaluation in late 
adolescence/young adulthood between the ages of 17-20 years reflects the need to avoid, “the 
confounding effect of variable age of onset of puberty whilst maintaining the opportunity to detect 
and address risk factors before adult patterns become established” (Sullivan et al., 2015, p. 3).  
There are currently numerous tests performed in the process of universal screening; therefore, a 
reliable and inexpensive method is required when screening for familial hypercholesterolemia. 
LDL-C and total cholesterol are relatively inexpensive and meet these requirements.  Genetic 
screening; however, is unsuitable for universal screening due to the complexity and high associated 
cost.  Testing for genetic mutations is more noted in populations in which a founder gene effect is 
present.  According to Sullivan et al. (2015), more research is needed for universal screening in 
order to convince providers to initiate it into clinical practice.  “Its implementation is likely to 
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require extensive education and appropriate allocation of resources” (Sullivan et al., 2015, p. 3).  
Universal screening requires wide-ranging awareness in order to promote participation and 
success. If implemented in childhood, universal screening for FH offers the opportunity to, 
“intervene before atherosclerosis and adverse lifestyle factors become entrenched, but a 
convincing argument must be mounted to win the support of the vast majority of the population” 
(Sullivan et al., 2015, p. 5).  Cascade screening may be difficult to prolong and sustain as it does 
not guarantee prevention of premature CVD due to FH.  However, universal screening requires 
extensive implementation. According to Sullivan et al. (2015), family cascade screening may offer 
an acceleration of case detection once universal screening has been established; thus, working 
synergistically.   
 One study conducted by Santos, Frauches, & Chacra (2015) discussed how cascade 
screening does present the risk of leaving people undiagnosed; thus, increasing evidence exists 
favoring a general population screening due to the low detection rates of cascade screening. 
Unfortunately, prior to the date of the publication no countries had reported on a universal 
screening program being implemented. The two most cited concerns regarding the universal 
screening would be cost and utilizations of resources during the implementation process.  
However, the cost could possibly be justified with the prevention of costly treatments of associated 
cardiovascular complications. The economic health cost of universal screening as well as early 
intervention costs that include follow-up and counseling disease management have not been well 
studied and these health economic questions need to be addressed with future research (Benuck, 
2015). Benuck (2015) discussed how “potentially significant risk factors leading to coronary artery 
disease may not be evident by either taking a careful medical and family history or performing a 
physical examination” (p. S99).  
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 McNeal, Toth, & Wilson (2015) address the issue of cost-effectiveness as it relates to 
universal screening by noting that this factor may be offset as this screening modality has the 
potential to detect FH in the parents of the affected youth through reverse cascade screening.  
Universal screening with reverse cascade screening may be the best tactic to identify the highest 
number of individuals with FH (McNeal et al., 2015). According to Pang et al. (2015), FH is quite 
prevalent among patients with a history of early-onset coronary artery disease in the coronary care 
unit (CCU). Due to the increased prevalence rates, genetic testing for FH is being completed in 
CCUs after severe complications have ensued. Recommendations from this study are to initiate 
screening tactics for FH to reduce the high costs associated with future complications of coronary 
artery disease as currently individuals are being diagnosed with FH while receiving critical care 
treatment that may have potentially been prevented.  
 According to Hartgers, Ray, & Hovingh (2015), when LDL particles accumulate in the 
arterial wall, the endothelial tissue becomes damaged and atherosclerotic plaques form. This 
process begins at a young age with endothelial function already impaired in a study of 
asymptomatic HeFH patients at the age of 9 to 18 years of age. The extent of atherosclerosis is 
enhanced by other risk factors such as diet and exercise, acknowledging the fact that childhood 
obesity is rapidly increasing. To date, universal screening has only recently been introduced in 
Slovenia for children at the age of 5. As previously noted by similar research, universal screening 
has been proposed in the U.S. at 9 and 11 years, perhaps at the same time as scheduled 
immunizations, and again in later adolescence/young adulthood.  “Ideally, this screening strategy 
would be integrated with cascade screening afterwards, to maximize the detection rate” (Hartgers 
et al., 2015, p. 4).  
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A recent study by Klancar et al. (2015) conducted on 279 Slovenian children between 1989 
and 2009 proves to be the only study completed to evaluate genetic identification of FH by a 
national universal screening for hypercholesterolemia. Altogether, 272 unrelated participants born 
between 1989 and 2009 had measurements of fasting serum triglycerides (TC) drawn during 
routine examination of 5-year old children by primary pediatricians.  Children with TC > 6 mmol/l 
or > 5 mmol/l plus a family history positive for premature cardiovascular complications identified 
in this universal screening were genotyped for genetic variants. Of the referred children, 57.0% 
carried disease-causing variants for FH. These findings note that family history alone may not 
suffice for appropriate identification of patients through the use of cascade screening. The findings 
support the latest recommendations; however, the U.S. recommendations are more specific on the 
age of the child during screening. Universal screening coupled with cascade screening for family 
members could be a “powerful approach for FH detection and prevention of cardiovascular 
complications” (Klancar et al., 2015, p. 1256).  This study was limited due to the small sample 
size; therefore, additional studies are recommended to confirm these results. Based on this study, 
pediatric cardiologist Dr. Stephen Daniels stated, “The finding of genetic variants in a large 
percentage of referred children without a family history of early CVD, supports the concept that 
the family history is not a reliable indicator of pediatric patients with FH” (Boyles, 2015, p. 3). Dr. 
Stephen Daniels went on to discuss that he supports the universal approach to screening for 
individuals with FH (Boyles, 2015).  
 Familial hypercholesterolemia is a serious disease that needs to be screened and treated as 
such.  Krogh, Mundal, Holven, & Retterstol (2015) conducted a study that assessed cardiovascular 
disease at the time of death in patients with familial hypercholesterolemia.  They found that the 
mean age at first CVD event was 44 years of age with the mean age at the time of death being 60 
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years of age. Of the 4,688 people that were studied, 50% of the deaths were due to cardiovascular 
disease.  These staggering statistics illustrate that immediate action is needed to promote early 
diagnosis and treatment for individuals with familial hypercholesterolemia.  
Learning Points 
The review of literature from this independent study illustrated the severity of familial 
hypercholesterolemia and the dire need for a consistent screening regimen.  Challenges to 
advancing familial hypercholesterolemia screening practices do exist in regards to integrating 
universal screening strategies into practice versus continuing to utilize cascade screening.  Even 
with these challenges, it is crucial to recognize the most important reason to initiate universal 
screening in the first place, which is to identify those children with FH in order to improve their 
lifespan.  Patients with heterozygous FH are at an increased risk of myocardial infarction due to 
the lifetime exposure of elevated LDL-C.  These myocardial infarctions in individuals with FH 
have occurred as early as the third decade of life.  “Unfortunately, the first clinical sign of 
disease in untreated heterozygous FH may be a myocardial infarction or sudden death” (Daniels, 
2015, p. 1).  Universal screening with appropriate guidelines for follow-up is relatively new and 
will take time for most practices to implement into their standard of care (Benuck, 2015, p. S99). 
Integrating the universal screening policy into practice remains one of the biggest challenges due 
to the wide-spread education that would be necessary for proper implementation. To conclude 
this independent study, the following bullet points are listed highlighting the important concepts 
to promote positive change as it relates to screening for familial hypercholesterolemia.  
 Cascade screening is currently being utilized as the predominant screening method for 
familial hypercholesterolemia.  Based on the literature review, this screening method 
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exhibits voids in effectiveness due to the large number of individuals with familial 
hypercholesterolemia remaining undiagnosed.  
 Universal screening may be a necessary process that needs to be implemented into 
clinical practice in order to consistently identify individuals with familial 
hypercholesterolemia. Implementing universal screening into clinical practice may lead 
to necessary surveillance and treatment of these individuals in order to improve and 
lengthen the overall lifespan.  
 Universal screening coupled with reverse cascade screening for family members could be 
a superior tactic to appropriately detect familial hypercholesterolemia; thus, averting 
complications.  
 Cost-effectiveness and implementation are both barriers that need to be overcome in 
order to successfully promote and integrate universal screening into clinical practice.  
The first universal screening research study completed in Slovenia as well as the release 
of the new guidelines and recommendations for universal screening to detect individuals 
with familial hypercholesterolemia will help force the issue to the public in order for 
further research to be conducted. Future studies regarding the cost-effectiveness and 
positive outcomes of initiating universal screening, especially in the young, are necessary 
to drive policy change.  
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